BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Special reports
Aging
Biosimilars
Artificial intelligence
Coronavirus
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Wednesday, January 31, 2024
See today's BioWorld Asia
Home
» Neuren’s NNZ-2591 meets endpoints in phase II trial in Phelan-McDermid syndrome
To read the full story,
subscribe
or
sign in
.
Neuren’s NNZ-2591 meets endpoints in phase II trial in Phelan-McDermid syndrome
Dec. 19, 2023
By
Tamra Sami
No Comments
Neuren Pharmaceuticals Ltd. plans to progress NNZ-2591 to phase III trials following positive top-line phase II results in children with Phelan-McDermid syndrome, a genetic neurodevelopmental disorder for which there are no approved treatments.
BioWorld Asia
Clinical
Neurology/psychiatric
Asia-Pacific
Australia
